Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation. [PDF]
Sci Rep, 2020 AbstractAflibercept (AFL) is an Fc fusion protein used in the treatment of colorectal cancers and different ophthalmological diseases. There are two medicines in which AFL is the active substance: Zaltrap and Eylea, referred as ziv-AFL and AFL respectively. No proper accelerated degradation studies were published on either AFL or ziv-AFL. These studies
Hermosilla J +6 more
europepmc +7 more sources
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study [PDF]
International Journal of Retina and VitreousPurpose To evaluate the structural and functional changes in eyes with neovascular age related macular degeneration (nAMD) in a real-world setting, using Treat and Extend protocol (T&E), comparing four antiangiogenic agents.
Tereza Kanadani +4 more
doaj +2 more sources
Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. [PDF]
Transl Vis Sci Technol, 2018 To evaluate retinal toxicity of ziv-aflibercept, a drug that had been approved for use for patients with colon cancer.Twenty-two albino rabbits were injected intravitreally with 0.1 mL of ziv-aflibercept solution into the experimental eye and 0.1-mL saline into the control eye. Twelve were used for electroretinogram (ERG) at 4-weeks follow-up.
Ramon D +5 more
europepmc +3 more sources
Ziv-aflibercept in metastatic colorectal cancer. [PDF]
Biologics, 2014 The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with
Patel A, Sun W.
europepmc +6 more sources
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer [PDF]
BMC Cancer, 2019 Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose ...
John H. Strickler +19 more
doaj +2 more sources
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy [PDF]
Indian Journal of Ophthalmology, 2019 Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV).
Sumit Randhir Singh +3 more
doaj +2 more sources
Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study [PDF]
Clinical Ophthalmology, 2018 Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland ...
Doepfner JM +4 more
doaj +2 more sources
Taiwan Journal of Ophthalmology, 2020 PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD).
Sumit Randhir Singh +7 more
doaj +2 more sources
Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept [PDF]
Clinical Ophthalmology, 2019 Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon; 3Medical School, Medical ...
Mansour AM, El Jawhari K, Arevalo JF
doaj +2 more sources
Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. [PDF]
Oncotarget, 2017 Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patients who did not respond to standard chemotherapy ...
Lu CS +11 more
europepmc +4 more sources